Issue: Issue 1 2012
January 01, 2012
1 min read
Save

Study suggests medial mobile bearing UKA not a temporary procedure

Issue: Issue 1 2012
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adolph V. Lombardi, Jr., MD
Adolph V. Lombardi, Jr.

Research presented recently by Adolph V. Lombardi, Jr., MD, supports the use of medial mobile bearing unicompartmental knee arthroplasty may provide a higher activity level and fewer complications than total knee arthroplasty, based on research presented here.

“Long-term data would refute that unicompartmental knee arthroplasty (UKA) is a temporary or pre-total knee arthroplasty procedure,” Lombardi said at the Current Concepts in Joint Replacement 2011 Winter Meeting.

In his presentation, Lombardi discussed the results of a retrospective multi-study analysis that he and colleagues conducted on the procedures performed between 2004 and 2008 contained in their institution’s electronic database. For the 1,000 consecutive medial mobile bearing UKA procedures evaluated, which were done in 808 patients, there was 96% survivorship at about 38 months follow-up.

Wear data for the mobile bearing UKA implants studied were also superior to the fixed bearing results in the same database, Lombardi said, adding there are no contraindications to using mobile bearing UKAs for all medial compartmental UKA procedures.

Lombardi noted that, while there were 40 revisions in his study, those revisions were done early at an average of 23.1 months follow-up.

Reference:
  • Lombardi AV. Mobile magic: Try it, you’ll like it! Paper #70. Presented at the Current Concepts in Joint Replacement 2011 Winter Meeting. Dec. 7-10. Orlando, Fla.
  • Disclosure: Lombardi receives royalties from, is a consultant to, is on the speaker’s bureau for, and receives research support from Biomet and receives royalties from Innomed.